tradingkey.logo
Search
Markets
Watchlist
News
Analysis
Tools
Stock Screener
English
繁体中文
ไทย
Tiếng việt
简体中文
Español
Português
Deutsch
한국어
日本語
tradingkey.logo
Search

Takeda Pharmaceutical Co Ltd

TAK
Add to Watchlist
16.835USD
-0.035-0.21%
Close 07-23 16:00（ET）Quotes delayed by 15 min
53.19BMarket Cap
43.89P/E TTM

Takeda Pharmaceutical Co Ltd

16.835
-0.035-0.21%
Overview
Financials
Discussions
Analysis
Company
Financial SummaryIncome StatementBalance SheetCash Flow Statement

Overview

Financials

Discussions

Analysis

Company

Financial SummaryIncome StatementBalance SheetCash Flow Statement

TAK Financials

See Takeda Pharmaceutical Co Ltd's financials through an all-in-one data dashboard designed for smart investors. This provides you with financial analysis by organizing complex financial statements into customizable views. Access the latest annual financial report or break down performance quarter-by-quarter using the income statement, balance sheet, and cash flow statement. With real-time financial indicators at your fingertips, monitoring a company's market health over time has never been easier.

Takeda Pharmaceutical Co Ltd Earnings Date

Latest Release
Jul 30, 2026
EPS / Forecast
--/0.86
Revenue / Forecast
--/7.19B
See Upcoming Earnings >>
Period
FY2026 Earnings
Revenue(YoY)
28.54B
-9.09%
EPS(YoY)
-0.30
-233.73%
Analyst Rating
BUY
2026/07/23
Quarterly
Quarterly+Annual
Quarterly
Annual
YOY
Hide blank rows
FY2026Q4
FY2026Q3
FY2026Q2
FY2026Q1
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021Q4
Financial Indicators
EPS
-237.52%-0.74
338.66%0.21
-112.49%-0.03
46.07%0.28
---0.22
-80.00%0.05
297.08%0.20
-5.27%0.19
----
-18.27%0.24
---0.10
--0.20
--0.08
--0.29
--107.62
----
----
----
----
----
----
Revenue
-3.95%6.93B
4.98%7.78B
-6.66%7.22B
-8.09%7.40B
3.95%7.22B
-2.29%7.41B
11.52%7.74B
6.09%8.05B
-2.28%6.95B
-10.96%7.59B
1.22%6.94B
4.83%7.59B
5.76%7.11B
8.71%8.52B
-7.89%6.85B
-16.34%7.24B
-5.25%6.72B
-1.10%7.84B
-1.36%7.44B
14.30%8.66B
----
Net Profit
-230.18%-2.33B
339.11%676.99M
-112.65%-76.58M
30.86%831.06M
-3444.49%-706.98M
-78.65%154.17M
289.56%605.45M
-0.94%635.07M
-108.62%-19.95M
-22.02%722.03M
-175.67%-319.39M
-18.02%641.10M
364.78%231.41M
84.25%925.98M
4.29%422.11M
-37.69%782.05M
-104.82%-87.40M
-42.57%502.57M
948.83%404.76M
61.06%1.26B
----
Net Margin
-243.91%-33.66%
317.84%8.70%
-113.46%-1.05%
42.35%11.23%
---9.79%
-78.11%2.08%
270.30%7.83%
-6.59%7.89%
----
-12.41%9.52%
---4.60%
--8.45%
--3.26%
--10.87%
--8.44%
----
----
----
----
----
----
Gross Margin
8.48%53.50%
5.94%54.91%
-1.15%54.04%
-5.20%53.55%
--49.32%
-3.67%51.83%
0.24%54.66%
-2.65%56.49%
----
-5.59%53.81%
--54.53%
--58.03%
--53.67%
--57.00%
--55.84%
----
----
----
----
----
----
Debt to assets ratio
-16.04%31.47%
-1.69%31.50%
-7.38%32.10%
-4.74%32.17%
--37.49%
-2.30%32.04%
10.16%34.66%
5.25%33.78%
----
3.31%32.79%
--31.46%
--32.09%
--31.40%
--31.74%
--32.47%
----
----
----
----
----
----
Income Statement
Revenue
-3.95%6.93B
4.98%7.78B
-6.66%7.22B
-8.09%7.40B
3.95%7.22B
-2.29%7.41B
11.52%7.74B
6.09%8.05B
-2.28%6.95B
-10.96%7.59B
1.22%6.94B
4.83%7.59B
5.76%7.11B
8.71%8.52B
-7.89%6.85B
-16.34%7.24B
-5.25%6.72B
-1.10%7.84B
-1.36%7.44B
14.30%8.66B
----
Operating profit
-349.72%-2.31B
160.13%1.14B
-25.03%926.15M
-1.61%1.25B
-288.17%-513.55M
-50.66%438.38M
208.55%1.24B
1.36%1.27B
-63.21%272.92M
-29.39%888.55M
-43.93%400.37M
11.82%1.25B
206.61%741.82M
0.98%1.26B
-35.34%714.01M
-53.65%1.12B
-85.40%241.94M
-19.78%1.25B
28.32%1.10B
33.93%2.42B
----
Net Profit
-230.18%-2.33B
339.11%676.99M
-112.65%-76.58M
30.86%831.06M
-3444.49%-706.98M
-78.65%154.17M
289.56%605.45M
-0.94%635.07M
-108.62%-19.95M
-22.02%722.03M
-175.67%-319.39M
-18.02%641.10M
364.78%231.41M
84.25%925.98M
4.29%422.11M
-37.69%782.05M
-104.82%-87.40M
-42.57%502.57M
948.83%404.76M
61.06%1.26B
----
Balance Sheet
Current assets
13.31%19.58B
14.04%20.36B
-5.66%18.95B
-18.87%16.81B
--17.28B
7.61%17.85B
22.70%20.09B
16.87%20.72B
----
-17.79%16.59B
-12.78%16.37B
-6.63%17.73B
-10.69%17.82B
-6.39%20.18B
-13.22%18.77B
-15.89%18.99B
-20.10%19.96B
-13.05%21.56B
-12.47%21.63B
-3.42%22.57B
8.25%24.98B
Total current liabilities
4.44%17.94B
25.40%17.05B
-11.59%13.88B
-11.71%14.51B
--17.18B
-12.77%13.60B
-0.27%15.70B
-8.39%16.44B
----
-10.35%15.59B
-3.71%15.74B
11.18%17.94B
11.73%18.45B
10.47%17.39B
-3.23%16.35B
3.72%16.14B
1.13%16.51B
-7.97%15.74B
3.38%16.90B
-18.91%15.56B
-19.70%16.33B
Total assets
0.63%98.27B
2.80%100.65B
-2.05%93.89B
-13.42%93.68B
--97.65B
0.79%97.91B
-3.07%95.86B
1.99%108.20B
----
-7.46%97.14B
-0.85%98.90B
1.28%106.09B
2.31%103.74B
-4.98%104.97B
-9.82%99.74B
-9.22%104.75B
-14.71%101.40B
-5.10%110.47B
-6.80%110.60B
-3.15%115.38B
-0.76%118.89B
Total liabilities
2.15%51.19B
1.80%50.72B
-5.39%47.62B
-15.03%47.75B
--50.12B
-2.48%49.82B
-2.98%50.33B
-0.44%56.20B
----
-10.31%51.09B
-3.65%51.87B
-2.17%56.45B
-2.00%56.51B
-11.12%56.96B
-15.50%53.84B
-14.68%57.70B
-19.03%57.67B
-11.55%64.09B
-13.97%63.72B
-9.63%67.63B
-5.83%71.22B
Total equity
-0.97%47.07B
3.85%49.93B
1.64%46.27B
-11.68%45.93B
--47.54B
4.42%48.08B
-3.18%45.53B
4.76%52.00B
----
-4.08%46.05B
2.45%47.02B
5.51%49.64B
8.00%47.23B
3.51%48.01B
-2.11%45.90B
-1.48%47.05B
-8.25%43.73B
5.52%46.38B
5.11%46.89B
7.79%47.75B
7.91%47.67B
Cash Flow Statement
Net operating income
-82.61%223.19M
-0.51%2.24B
32.99%2.22B
28.76%1.33B
-24.40%1.28B
181.06%2.26B
48.73%1.67B
98.33%1.03B
-15.93%1.70B
-70.03%802.33M
-13.95%1.12B
13.71%520.55M
-25.50%2.02B
-2.39%2.68B
-27.19%1.31B
-65.04%457.78M
-22.07%2.71B
59.62%2.74B
-17.98%1.79B
19.87%1.31B
----
Net investment
-172.49%-367.55M
-100.44%-1.50B
36.80%-312.31M
78.75%-222.03M
66.81%-134.88M
-45.68%-748.90M
-22.68%-494.19M
45.34%-1.04B
87.53%-406.34M
-41.65%-514.06M
-116.58%-402.84M
-170.99%-1.91B
-1552.10%-3.26B
39.66%-362.92M
35.81%-186.00M
-9.84%-705.35M
-107.30%-197.28M
-188.19%-601.46M
-209.97%-289.75M
-10370.69%-642.16M
----
Net financing
86.77%-241.96M
73.56%-1.06B
128.00%153.28M
-159.92%-1.33B
-657.65%-1.83B
-755.54%-4.02B
25.69%-547.35M
912.70%2.21B
-311.04%-241.44M
84.93%-469.79M
-391.32%-736.53M
81.05%-272.25M
106.74%114.40M
-163.89%-3.12B
92.19%-149.91M
59.36%-1.44B
46.88%-1.70B
52.67%-1.18B
3.53%-1.92B
-130.27%-3.54B
----

FAQs

What is the total revenue of Takeda Pharmaceutical Co Ltd?

According to Takeda Pharmaceutical Co Ltd's FY2026 earnings report, its total revenue reached 28.54B, with a year-on-year change of 31.40B.

What are the current assets of Takeda Pharmaceutical Co Ltd?

According to Takeda Pharmaceutical Co Ltd's FY2026 earnings report, its current assets were 19.58B, with a year-on-year change of 13.31.

What are the total assets of Takeda Pharmaceutical Co Ltd?

According to Takeda Pharmaceutical Co Ltd's FY2026 earnings report, its total assets of Takeda Pharmaceutical Co Ltd were 98.27B, with a year-on-year change of 0.63.

What are the total liabilities of Takeda Pharmaceutical Co Ltd?

According to Takeda Pharmaceutical Co Ltd's FY2026 earnings report, its total liabilities of Takeda Pharmaceutical Co Ltd were 51.19B, with a year-on-year change of 2.15.

What is the total equity of Takeda Pharmaceutical Co Ltd?

According to Takeda Pharmaceutical Co Ltd's FY2026 earnings report, its total equity of Takeda Pharmaceutical Co Ltd was 47.07B, with a year-on-year change of -0.97.

What is the net operating income of Takeda Pharmaceutical Co Ltd?

According to Takeda Pharmaceutical Co Ltd's FY2026 earnings report, its net operating income of Takeda Pharmaceutical Co Ltd was 4.21B, with a year-on-year change of 10.85.

What is the net investment of Takeda Pharmaceutical Co Ltd?

According to Takeda Pharmaceutical Co Ltd's FY2026 earnings report, its net investment of Takeda Pharmaceutical Co Ltd was -2.34B, with a year-on-year change of 7.04.

What is the net financing of Takeda Pharmaceutical Co Ltd?

According to Takeda Pharmaceutical Co Ltd's FY2026 earnings report, its net financing of Takeda Pharmaceutical Co Ltd was -2.38B, with a year-on-year change of 45.64.

What is the Earnings Per Share (EPS) of Takeda Pharmaceutical Co Ltd?

According to Takeda Pharmaceutical Co Ltd's FY2026 earnings report, its Earnings Per Share (EPS) was -0.30, with a year-on-year change of -233.73.

What is the net income of Takeda Pharmaceutical Co Ltd?

According to Takeda Pharmaceutical Co Ltd's FY2026 earnings report, its net income was -965.41M, with a year-on-year change of -230.52.

What is the net margin of Takeda Pharmaceutical Co Ltd?

According to Takeda Pharmaceutical Co Ltd's FY2026 earnings report, its net profit margin was -3.38, with a year-on-year change of -243.04.

What is the gross margin of Takeda Pharmaceutical Co Ltd?

According to Takeda Pharmaceutical Co Ltd's FY2026 earnings report, its gross margin was 54.09, with a year-on-year change of 1.03.

What is the debt-to-asset ratio of Takeda Pharmaceutical Co Ltd?

According to Takeda Pharmaceutical Co Ltd's FY2026 earnings report, its debt-to-asset ratio was 31.47, with a year-on-year change of -0.69.

What is the Return on Assets (ROA) of Takeda Pharmaceutical Co Ltd?

According to Takeda Pharmaceutical Co Ltd's FY2026 earnings report, its Return on Assets (ROA) was -1.02, with a year-on-year change of -238.77.

What is the operating profit of Takeda Pharmaceutical Co Ltd?

According to Takeda Pharmaceutical Co Ltd's FY2026 earnings report, its operating profit was 4.21B, with a year-on-year change of 10.85.
tradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.
General Terms of Use
Privacy Policy
Cookie Policy